- Home
- ADBE vs SNY Comparison
ADBE vs SNY Comparison
Compare ADBE & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADBE | SNY |
|---|---|---|
| Founded | 1982 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.0B | 119.4B |
| IPO Year | 1986 | N/A |
Fundamental Metrics
Financial Performance| Metric | ADBE | SNY |
|---|---|---|
| Price | $298.73 | $46.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 6 |
| Target Price | ★ $420.35 | $61.50 |
| AVG Volume (30 Days) | ★ 4.2M | 2.8M |
| Earning Date | 03-12-2026 | 01-29-2026 |
| Dividend Yield | N/A | ★ 3.44% |
| EPS Growth | 35.11 | ★ 105.93 |
| EPS | ★ 16.70 | 8.67 |
| Revenue | $23,769,000,000.00 | ★ $53,890,648,839.00 |
| Revenue This Year | $11.70 | $1.73 |
| Revenue Next Year | $9.10 | $6.49 |
| P/E Ratio | $17.95 | ★ $10.60 |
| Revenue Growth | ★ 10.53 | N/A |
| 52 Week Low | $288.33 | $44.62 |
| 52 Week High | $465.70 | $60.12 |
Technical Indicators
Market Signals| Indicator | ADBE | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 30.85 | 40.86 |
| Support Level | $288.33 | $45.25 |
| Resistance Level | $343.95 | $48.17 |
| Average True Range (ATR) | 8.64 | 0.73 |
| MACD | -4.51 | -0.16 |
| Stochastic Oscillator | 18.17 | 32.27 |
Price Performance
Historical ComparisonAbout ADBE Adobe Inc.
Adobe provides content creation, document management, and digital marketing and advertising software and services to creative professionals and marketers for creating, managing, delivering, measuring, optimizing, and engaging with compelling content multiple operating systems, devices, and media. The company operates with three segments: digital media content creation, digital experience for marketing solutions, and publishing for legacy products (less than 5% of revenue).
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.